| Source: |
| Type: general indicator |
| Anticancer Effect |
| 7356- | HibSad, | Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 7454- | HNK, | Updated progression of honokiol in lung cancer treatment |
| - | Review, | Lung, | NA |
| 7455- | HNK, | Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies |
| - | Review, | Var, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| 4522- | HNK, | MAG, | Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth |
| - | in-vitro, | HNSCC, | FaDu |
| 7371- | HOO, | Phytochemical characterization of peanut oil and its ozonized form to explore biological activities in vitro |
| - | in-vitro, | Colon, | NA |
| 7472- | Hops, | Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids |
| - | in-vitro, | BC, | SkBr3 |
| - | in-vitro, | AML, | Jurkat | - | in-vitro, | AML, | HL-60 | - | in-vitro, | NA, | 1- |
| 4634- | HT, | Hydroxytyrosol in cancer research: recent and historical insights on discoveries and mechanisms of action |
| - | Review, | Var, | NA |
| 4633- | HT, | Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells |
| - | in-vitro, | BC, | NA |
| 7567- | HYP, | Hyperoside: A review on its sources, biological activities, and molecular mechanisms |
| - | Review, | Var, | NA |
| 7550- | HYP, | Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | 4T1 |
| 7552- | HYP, | Hyperoside exerts potent anticancer activity in skin cancer |
| - | vitro+vivo, | Melanoma, | NA |
| 7609- | I3C, | Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives |
| - | Review, | Var, | NA |
| 7385- | IBC, | Fighting cancer by triggering non-canonical mitochondrial permeability transition-driven necrosis through reactive oxygen species induction |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | 4T1 |
| 7801- | IBC, | Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter |
| - | in-vitro, | CRC, | HT-29 |
| 7769- | IBC, | Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters |
| - | in-vivo, | Var, | NA |
| 7630- | Ins, | Modulation of both Insulin Resistance and Cancer Growth by Inositol |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| 7629- | Ins, | Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol |
| - | in-vivo, | Lung, | NA |
| 7648- | Ins, | Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol |
| - | in-vivo, | Liver, | NA |
| 7639- | Ins, | Myo-Inositol Reverses TGF-β1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells |
| - | in-vitro, | Nor, | MCF10 |
| 7641- | Ins, | Overview of Inositol and Inositol Phosphates on Chemoprevention of Colitis-Induced Carcinogenesis |
| - | Review, | CRC, | NA |
| 7632- | Ins, | The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor |
| - | Review, | Var, | NA |
| 7677- | iod, | Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone |
| - | in-vitro, | BC, | MCF7 |
| 7682- | iod, | Molecular Iodine Induces Anti- and Pro-Neoplastic Effects in Prostate Cancer Models |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7728- | IP6, | G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6) |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HT-29 |
| 7723- | IP6, | Prostate cancer and inositol hexaphosphate: efficacy and mechanisms |
| - | Review, | Pca, | NA |
| 7726- | IP6, | Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation |
| - | in-vitro, | BC, | MCF7 |
| 7695- | IP6, | The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells |
| - | in-vitro, | Colon, | Caco-2 |
| 7642- | IP6, | Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway |
| - | in-vitro, | CRC, | NA |
| 7645- | IP6, | Ins, | Anticancer Properties of Inositol Hexaphosphate and Inositol: An Overview |
| - | in-vitro, | Var, | NA |
| 7690- | IP6, | Ins, | Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application |
| - | Review, | Colon, | NA |
| 7696- | IP6, | Ins, | The Combination of Inositol Hexaphosphate and Inositol Inhibits Metastasis of Colorectal Cancer Cells by Upregulating Claudin 7 |
| - | vitro+vivo, | Colon, | SW48 | - | in-vitro, | Colon, | SW-620 |
| 7701- | IP6, | Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway |
| - | vitro+vivo, | HCC, | Hep3B | - | NA, | NA, | MHCC-97H |
| 7750- | ISL, | Isoliquiritigenin in Breast Cancer: A Systematic Review of Its Preventive and Anti-metastatic Mechanisms |
| - | Review, | BC, | NA |
| 7745- | ISL, | Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway |
| - | in-vitro, | CRC, | NA |
| 7746- | ISL, | Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HCT116 |
| 7756- | ISL, | Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 7763- | ISL, | Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 7765- | ISL, | Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications |
| - | Review, | Var, | NA |
| 7868- | isoO, | Isoorientin Suppresses Invasion of Breast and Colon Cancer Cells by Inhibition of CXC Chemokine Receptor 4 Expression |
| - | in-vitro, | BC, | NA | - | in-vitro, | CRC, | NA |
| 7814- | ISQ, | Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90 |
| - | in-vivo, | Nor, | NA |
| 7800- | ISQ, | Isoquercitrin Attenuates Oxidative Liver Damage Through AMPK-YAP Signaling: An Integrative In Silico, In Vitro, and In Vivo Study |
| - | vitro+vivo, | Nor, | HepG2 |
| 9173- | ITCs, | SFN, | Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management |
| - | Review, | Var, | NA |
| 9193- | ITCs, | PEITC, | BITC, | SFN, | Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research |
| - | Review, | Var, | NA |
| 8001- | itraC, | Repurposing itraconazole as an anticancer agent |
| - | Review, | Var, | NA |
| 8035- | IVM, | Ivermectin and non-parasitic disorders: An update |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 8049- | IVM, | Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer |
| - | vitro+vivo, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:813 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid